Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. IONS
4. AAPL
5. ACN
6. AZN
7. ROIV
8. HOOD
9. QCOM
10. NVDA

Go back to Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1
(NASDAQ: ACRS) Delayed: 6.11 -0.06 (0.97%)
Previous Close $6.17    52 Week High $33.88 
Open $6.08    52 Week Low $14.12 
Day High $6.15    P/E N/A 
Day Low $5.92    EPS $0.00 
Volume 1,210,933